RGene Therapeutics Inc. regulatory update

RGene's RGG0853 gene therapeutic received Orphan Drug Designation from the FDA for advanced ovarian cancer that overexpresses the HER-2/neu oncogene. Elevated levels of HER-2/neu are highly correlated with poor survival rates in women with ovarian cancer. ...